Simplicity 

Omnipod 5 is the only tubeless AID in the US. It is indicated for people with type 1 and type 2 diabetes and was designed to simplify life for them and diabetes management for you and your care team. This means: 

• Waterproof design, offering patients an on-body experience²  
• No need to disconnect from therapy during showering, swimming, sports, intimacy or any other activities of daily living³   
• Caregivers can remotely administer boluses via the Controller or compatible smartphone⁴ without needing to interrupt play    
• Automatic wireless data uploads help you make clinical decisions with confidence⁵ 

Clinical Results 

We believe simplicity leads to results. Omnipod 5 delivers clinical results in both pivotal clinical trials and in the real world.

• The RADIANT Randomized Controlled Trial showed improved time in range by an average of 23% for T1D adults and 20% for children and adolescents with T1D, compared with MDI users⁶
• The SECURE T2D study showed a 2.1% decrease in A1C for people living with type 2 diabetes with a baseline A1C ≥9% without increasing hypoglycemia⁷
• Additionally, Forlenza et al. conducted a real-world data analysis of nearly 70,000 Omnipod 5 T1D users, representing 17.7 million days of use in a non-clinical setting⁸. This is the largest published US data set in the current AID landscape. The authors concluded that glycemic results from this “large and diverse sample … demonstrate effective use of the Omnipod 5 system under real-world conditions.”⁸ Results of note include:
  • Former MDI patients had a 70.8% TIR and time <70mg/dL was 0.96% at an average target of 110mg/dL.⁹ 
  • The Medicare insurance cohort (median age 67 years) had a median TIR of 72.3% and time <70 mg/dL of 0.91% at an average target of 110 mg/dL.¹⁰ This finding is especially useful for HCPs who might be hesitant to give older patients cutting-edge technology.  
  • Overall TIR for the full cohort was almost 70% with only 1.12% of time spent in hypoglycemia at an average target of 110 mg/dL.¹¹ 
  • Average time in automated mode was nearly 94%, as patients don’t have to disconnect during daily activities.^{3, 12} 

Access 

The simplest, most efficacious therapy would be of little use if patients couldn’t access it. This is why you can prescribe Omnipod the same way as prescribing insulin, without DME hurdles. 

• Omnipod 5 is available through the pharmacy so that patients aren’t locked into a four-year DME lock-in period. Your patients can get started today!¹³ 
• Over 90% insurance coverage, representing over 300 million covered lives and we keep working to expand this number.¹⁴ 
• More than half of covered Omnipod 5 scripts are filled within 24 hours through the pharmacy.¹⁵ 
• The majority of Omnipod 5 customers pay $30 or less per month.¹⁶ 

1. Omnipod was the pump most frequently requested by people with type 1 and type 2 diabetes in a survey with Endocrinologists conducted by dQ&A across the United States. n=77 (T1) and n=63 (T2); H2 2024; P.25
2. The Pod has an IP28 rating for up to 25 feet for 60 minutes. The Controller is not waterproof. 
3. Device components including the Pod, CGM transmitter, and CGM sensor may be affected by strong radiation or magnetic fields. Device components must be removed (and the Pod and CGM sensor should be disposed of) before X-ray, Magnetic Resonance Imaging (MRI), or Computed Tomography (CT) scan (or any similar test or procedure). In addition, the Controller and smartphone should be placed outside of the procedure room. Exposure to X-ray, MRI, or CT, treatment can damage these components. Check with your healthcare provider on Pod removal guidelines. 
4. For a list of compatible smartphone devices visit omnipod.com/compatibility. 
5. Must be connected to WiFi or cellular data, and Omnipod 5 users must have WiFi or cellular data access to receive updates in Glooko. 
6. Wilmot E, et al. Presented at: ATTD; March 19-22, 2025; Amsterdam, NL. A 13-week randomized, parallel-group clinical trial conducted among 188 participants (age 4-70) with type 1 diabetes in France, Belgium, and the U.K., comparing the safety and effectiveness of the Omnipod 5 System versus multiple daily injections with CGM
7. Pasquel FJ, et al. JAMA Network Open (2025). Prospective pivotal trial in 305 participants with T2D aged 18-75 yrs. Study included a 14-day standard therapy (ST) phase followed by a 13-week Omnipod 5 hybrid closed-loop phase. Mean time in range (70-180 mg/dL): ST vs. 13-week Omnipod 5: 45% vs. 66%, P<0.001. Mean HbA1c: ST vs. 13-week Omnipod 5: 8.2% vs. 7.4%, P<0.001. In a subgroup analysis of 68 participants with baseline A1c ≥ 9% Mean HbA1c: ST vs. 13-week Omnipod 5: 10.1% vs. 8.1%, P<0.001. Mean T2-DDAS total intensity score: ST = 2.5, 3-month Omnipod 5 = 2.2, P<0.001. Mean Proportion with T2-DDAS ≥ 2.0, no. (%): ST = 66%; 3-month Omnipod 5 = 55%, P<0.001
8. Forlenza G, et al. Real-world evidence of Omnipod 5 Automated Insulin Delivery System use in 69,902 people with type 1 diabetes. Diabetes Technol Ther. 2024. 
9. Forlenza G, et al. Diabetes Technol Ther (2024). 6,525 Omnipod 5 users with type 1 diabetes at the Target Glucose of 110 mg/dL who utilized MDI as prior therapy had a time in range of 70.8% and a TBR of 0.96%. Omnipod 5 results based on users with ≥90 days CGM data, ≥75% of days with ≥220 readings available. 
10. Forlenza G, et al. Diabetes Technol Ther (2024). 61,503 Omnipod 5 users with type 1 diabetes at the Target Glucose of 110 mg/dL who had Medicare insurance had a time in range of 72.3% and a TBR of 0.91%. Omnipod 5 results based on users with ≥90 days CGM data, ≥75% of days with ≥220 readings available. 
11. Forlenza G, et al. Diabetes Technol Ther (2024). Real-world data from 37,640 Omnipod 5 users with type 1 diabetes at the Target Glucose of 110 mg/dL had a median TIR (70-180 mg/dL) of 68.8% and a median TBR of 1.12%. Omnipod 5 results based on users with ≥90 days CGM data, ≥75% of days with ≥220 readings available. 
12. Forlenza G, et al. Real-world evidence of Omnipod 5 Automated Insulin Delivery System use in 69,902 people with type 1 diabetes resulted in 93.7% time in Automated Mode. Diabetes Technol Ther. 2024 
13. Only available for users with valid prescription and coverage through their pharmacy benefit. Exact coverage depends on patient’s insurance plan. Upgrades subject to user’s insurance coverage. 
14. Reflects coverage for Omnipod 5 G6 Intro Kit and Omnipod 5 G6 Pods. Source: Managed Markets Insights & Technology, LLC.as of September 2024
15. Calculated based on the proportion of script fills within a 24-hour look forward period out of all script fills within a 90-day look forward period among all new to brand commercial, Medicare and Medicaid claims for the Omnipod 5 G6 Intro Kit from January 2023 to December 2023. Source: IQVIA Payer Control Library
16. Majority defined as at least 50% of patient co-pays $30 or less per month. Among All Paid Omnipod 5 G7G6 Pods Commercial and Medicare Claims from January 2024 to December 2024. Includes benefits and offerings available through Insulet, such as the copay card program. Actual co-pay amount depends on patient’s health plan and coverage, they may fluctuate and be higher or lower than the advertised amount on a monthly basis.  Source: IQVIA OPC Library

The Omnipod® 5 Automated Insulin Delivery System is a single hormone insulin delivery system intended to deliver U-100 insulin subcutaneously for the management of type 1 diabetes in persons aged 2 and older requiring insulin and type 2 diabetes in persons aged 18 and older. Rx only.  WARNING: Do not use SmartAdjust™ technology for people under the age of 2 or who require less than 5 U of insulin per day. Visit omnipod.com/safety for complete safety information.

Insulet, Omnipod and the Omnipod logos are trademarks or registered trademarks of Insulet Corporation in the United States of America and other various jurisdictions and are used with permission. All rights reserved.